Loading…
French-founded global testing, inspection and laboratory services company covering food, environment, pharma and genomics.
French-founded global testing, inspection and laboratory services company covering food, environment, pharma and genomics.
Charges per test or per project for lab analysis, often under recurring routine-testing contracts, so work is steady and tied to regulation and quality-control rules rather than customers' sales. It grew mainly by buying small labs. The Martin family, led by founder Gilles Martin, keeps control through its holding company.
Moat: narrow (scale, distribution, regulatory licence). Dense global lab network built through hundreds of acquisitions gives scale and local accreditation.
Headquarters: Luxembourg · Founded: 1987 · Employees: 65,694
Size Eurofins Scientific (ERF.PA) is a France Industrials company (Miscellaneous Commercial Services) with a market value of $17.5B, the 36th largest of 206 France companies the cockpit tracks. Shares closed at €88.64 on 6 Nov 2026.
Performance Over six months the shares gained 49.2%, against +7.6% for the median peer and -0.4% for the France market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue grew 3.4% over the last twelve months (peer median +4.9%); the operating margin is 12.5% (peer median 15.5%).
Valuation It trades at 23.0× forward earnings against a peer median of 21.4× (9th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points above its cost of capital (7.7% WACC).
Credit Eurofins Scientific has 6 bonds outstanding ($3.84B), rated Baa3 by the agencies and trading like BBB at a weighted spread of 116 bp.
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €7.39B | €7.30B | €6.95B | €6.51B | €6.71B |
| Revenue growth | — | +5% | +7% | -3% | — |
| Gross profit | €920M | €897M | €794M | €620M | €824M |
| EBITDA | €1.63B | €1.54B | €1.42B | €1.21B | €1.39B |
| Net income | €530M | €475M | €406M | €310M | €610M |
| Free cash flow | €634M | €534M | €770M | €469M | €513M |
| Capital expenditure | €806M | €835M | €528M | €550M | €660M |
| Total debt | n/a | €5.43B | €4.61B | €4.93B | €3.91B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Eurofins Scientific ERF.PA | $17.5B | +49% | +3% | 12% | 23.0× | 13.3% |
| Sgs SGSN.SW | $24.8B | +21% | +5% | 15% | 24.5× | 3.1% |
| Bureau Veritas BVI.PA | $14.9B | +13% | +2% | 15% | 20.2× | 7.9% |
| Intertek ITRK.L | $12.3B | +12% | +4% | 18% | 22.3× | 14.8% |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ERF.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.1% | +10.8% | 6th highest of 21 |
| 6-month return | +49.2% | +7.6% | 2nd highest of 21 |
| Distance from 52-week high | -0.7% | -15.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +3.4% | +4.9% | 7th lowest of 21 |
| Operating margin | 12.5% | 15.5% | 6th lowest of 21 |
| Forward P/E | 23.0× | 21.4× | 9th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 13.3% | 7.9% | 5th most demanding of 20 |
| Growth delivered (Del g) | +6.1% | +7.5% | 7th lowest of 20 |
| Hurdle (Req g minus delivered) | +7.2 pp | -1.3 pp | 4th most demanding of 20 |
| ROIC minus cost of capital | +0.3 pp | +8.5 pp | 5th lowest of 20 |
| EV / EBITDA | 12.6× | 12.8× | 10th cheapest of 20 |
| Net debt / EBITDA | 3.0× | 1.8× | 2nd most indebted of 20 |
| Bond spread | 116 bp | 99 bp | 3rd widest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Eurofins Scientific ERF.PA | France | $17.5B | +49% | +3% | 12% | 23.0× | 13.3% | +6.1% |
| Computershare CPU.AX | Australia | $17.2B | +44% | 0% | 30% | 19.1× | -2.6% | +9.2% |
| Rollins ROL | United States | $18.1B | -29% | +8% | 19% | 31.4× | 11.2% | +11.7% |
| Secom 9735.T | Japan | $18.8B | +16% | +4% | 13% | 22.7× | -0.3% | +3.9% |
| UL Solutions ULS | United States | $15.9B | -22% | +6% | 19% | 31.2× | 9.1% | +5.8% |
| Bureau Veritas BVI.PA | France | $14.9B | +13% | +2% | 15% | 20.2× | 7.9% | +7.0% |
| Sgs SGSN.SW | Switzerland | $24.8B | +21% | +5% | 15% | 24.5× | 3.1% | +4.4% |
| Intertek ITRK.L | United Kingdom | $12.3B | +12% | +4% | 18% | 22.3× | 14.8% | +4.6% |
| CETC Lantian Technology 688818.SS | China | $12.1B | -33% | +5% | 9% | 214.2× | n/a | n/a |
| Rentokil Initial RTO.L | United Kingdom | $11.9B | -26% | 0% | 14% | 16.9× | 8.2% | +13.4% |
| Baycurrent 6532.T | Japan | $11.2B | +132% | +32% | 33% | 35.6× | 6.4% | +28.2% |
| Booz Allen Hamilton BAH | United States | $10.1B | +11% | -6% | 9% | 13.3× | -7.0% | +7.4% |
| Adyen ADYEN.AS | Netherlands | $32.0B | 0% | +17% | 42% | 23.7× | 18.9% | -6.0% |
| Securitas SECU-B.ST | Sweden | $9.22B | +4% | -5% | 7% | 12.3× | -4.9% | +7.5% |
| Universal Music UMG.AS | Netherlands | $35.3B | -15% | +5% | 16% | 16.9× | 7.1% | +11.0% |
| CAE CAE.TO | Canada | $8.67B | +3% | +5% | 13% | 29.5× | 13.2% | +10.5% |
| Spie SPIE.PA | France | $8.64B | -8% | +3% | 6% | 14.5× | 8.6% | +9.3% |
| Experian EXPN.L | United Kingdom | $36.1B | +16% | +7% | 25% | 20.5× | 14.6% | +8.9% |
| ALS ALQ.AX | Australia | $7.40B | -3% | +11% | 17% | 23.6× | 23.0% | +13.5% |
| Iss A/s ISS.CO | Denmark | $7.08B | +13% | +4% | 5% | 15.3× | -6.1% | +3.7% |
| Genpact G | United States | $7.07B | +30% | +7% | 16% | 9.9× | -7.5% | +6.5% |
Eurofins Scientific has 6 bonds outstanding with $3.84B face value. The agencies rate it Baa3; its bonds trade like BBB. Weighted yield 4.16%, a spread of 116 bp over government bonds.